Cancer
Malignant Esophageal Neoplasm
CI-CAN-00001127Explore in graph →
Top-level518 active trials6 approved drugs12 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001127Explore in graph →
Clinical trials
1,926 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (169)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00006472 | Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer | terminated | Phase 2 | 4 | Medstar Health Research InstituteOTHER | 1 | Aug 18, 2020 | clinicaltrials |
| NCT03187314 | Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal Cancer | completed | Phase 2 | 25 | Hangzhou Cancer HospitalOTHER | 1 | Aug 17, 2020 |
| NCT04512417 | A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer | unknown | Phase 2 | 63 | Zhejiang Cancer HospitalOTHER | 1 | Aug 13, 2020 | clinicaltrials |
| NCT04503967 | Efficacy and Safety of Anlotinib Hydrochloride Combined With Nivolumab in the Treatment of Gastric and Esophageal Cancer(OASIS) | unknown | Phase 2 | 48 | Shanghai Zhongshan HospitalOTHER | 0 | Aug 7, 2020 | clinicaltrials |
| NCT00985192 | Everolimus in Treating Patients With Previously Treated Unresectable or Metastatic Esophageal Cancer or Stomach Cancer | completed | Phase 2 | 49 | Translational Oncology Research InternationalOTHER | 1 | Aug 5, 2020 | clinicaltrials |
| NCT00003748 | Irinotecan in Treating Patients With Esophageal or Stomach Cancer | completed | Phase 2 | 40 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT00020761 | Irinotecan and Paclitaxel in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus or Stomach | completed | Phase 2 | 51 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 3, 2020 | clinicaltrials |
| NCT02120911 | Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma(TRAP) | completed | Phase 1 / Phase 2 | 40 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04437212 | Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Locally Advanced Esophageal Cancer | unknown | Phase 2 | 20 | RenJi HospitalOTHER | 1 | Jun 26, 2020 | clinicaltrials |
| NCT02017600 | A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus | terminated | Phase 2 | 48 | Nang Kuang Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 20, 2020 | clinicaltrials |
| NCT01913639 | FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer | completed | Phase 2 | 39 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2020 | clinicaltrials |
| NCT03087864 | PDL-1 Targeting in Resectable Oesophageal Cancer(PERFECT) | completed | Phase 2 | 40 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | May 11, 2020 | clinicaltrials |
| NCT02279134 | Phase II/III Study Compare Adjuvant Chemoradiotherapy, Radiotherapy and Surgery Alone for Esophageal Carcinoma | unknown | Phase 2 / Phase 3 | 360 | Zefen XiaoUNKNOWN | 1 | Apr 3, 2020 | clinicaltrials |
| NCT00539617 | Chemotherapy & Erlotinib in Treating Patients w/ Esophageal or Gastroesophageal Cancer That Cannot Be Removed by Surgery | terminated | Phase 2 | 7 | University of California, San FranciscoOTHER | 1 | Mar 23, 2020 | clinicaltrials |
| NCT02123381 | Changes in Tumor Tissue and Serum Biomarkers Before and After Cetuximab Combined With Preoperative Radiotherapy in Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 100 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT01787006 | Definitive Radiochemotherapy Plus/Minus Cetuximab in Unresectable Locally Advanced Esophageal Cancer | completed | Phase 2 | 74 | University Hospital Schleswig-HolsteinOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT01362127 | Neoadjuvant Chemotherapy Versus Radiochemotherapy for Cancer of the Esophagus or Cardia(NeoRes) | completed | Phase 2 | 181 | Karolinska University HospitalOTHER | 1 | Feb 26, 2020 | clinicaltrials |
| NCT00439608 | Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer | completed | Phase 2 | 60 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT00522795 | Neoadjuvant Paclitaxel Poliglumex, Cisplatin and Radiation for Esophageal Cancer: A Phase II Trial (CTI#X64001) | completed | Phase 2 | 40 | Brown UniversityOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT03603756 | SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer | unknown | Phase 2 | 45 | Chinese Academy of Medical SciencesOTHER | 1 | Feb 11, 2020 | clinicaltrials |
| NCT01747551 | FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer | completed | Phase 2 | 64 | Dana-Farber Cancer InstituteOTHER | 1 | Feb 10, 2020 | clinicaltrials |
| NCT03818997 | Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer(DYNAMIC) | withdrawn | Phase 2 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | Feb 5, 2020 | clinicaltrials |
| NCT03913182 | Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer | unknown | Phase 2 | 39 | Shanghai Chest HospitalOTHER | 1 | Feb 5, 2020 | clinicaltrials |
| NCT01348217 | Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus(CONCORDE) | completed | Phase 2 / Phase 3 | 196 | Centre Georges Francois LeclercOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT04229849 | Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 164 | Henan Cancer HospitalOTHER_GOV | 0 | Jan 18, 2020 | clinicaltrials |
| NCT03139487 | A Randomized Phase II Open Label Study to Compare the Safety and Efficacy of Subcutaneous Dalteparin Versus Direct Oral Anticoagulants for Cancer-associated Venous Thromboembolism(PRIORITY) | unknown | Phase 2 | 176 | Asan Medical CenterOTHER | 1 | Jan 6, 2020 | clinicaltrials |
| NCT01624090 | Mithramycin for Lung, Esophagus, and Other Chest Cancers | terminated | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Dec 30, 2019 | clinicaltrials |
| NCT04006041 | Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Cancer | unknown | Phase 2 | 44 | Jianhua FuOTHER | 1 | Dec 26, 2019 | clinicaltrials |
| NCT03985670 | Teripalimab Plus Chemotherapy in Local Advanced Esophageal Cancer | unknown | Phase 2 | 30 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 12, 2019 | clinicaltrials |
| NCT02520453 | Adjuvant Durvalumab for Esophageal Cancer | unknown | Phase 2 | 86 | Samsung Medical CenterOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT01498289 | S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer | completed | Phase 2 | 213 | SWOG Cancer Research NetworkNETWORK | 1 | Nov 7, 2019 | clinicaltrials |
| NCT04137679 | Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO | unknown | Phase 2 | 60 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 1, 2019 | clinicaltrials |
| NCT02318901 | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer(PembroMab) | terminated | Phase 1 / Phase 2 | 16 | Western Regional Medical CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT04115618 | SIB in Upper Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 65 | Fudan UniversityOTHER | 1 | Oct 4, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01059643 | A Study in Ovarian, Non-Small Cell Lung, Prostate, Colorectal, Gastroesophageal Cancers, and Squamous Cell Carcinoma of the Head and Neck | completed | Phase 2 | 103 | Eli Lilly and CompanyINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT02843581 | Combination of Cryosurgery and NK Immunotherapy for Advanced Esophageal Cancer | completed | Phase 1 / Phase 2 | 60 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Sep 12, 2019 | clinicaltrials |
| NCT04054518 | Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma(DESC) | unknown | Phase 2 | 22 | Tiago BiachiOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03185988 | Anti-HER2 Therapy in Patients of HER2 Positive Metastatic Carcinoma of Digestive System | unknown | Phase 2 | 100 | Shen LinOTHER | 1 | Jul 19, 2019 | clinicaltrials |
| NCT01855854 | Second-line Treatment With Icotinib in Esophageal Carcinoma Patients With EGFR Overexpression (IHC 3+) or Positive FISH | completed | Phase 2 | 54 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jul 5, 2019 | clinicaltrials |
| NCT03940976 | Afatinib in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification (ESCC-A01) | unknown | Phase 2 | 40 | Peking UniversityOTHER | 1 | Jun 11, 2019 | clinicaltrials |
| NCT02649361 | Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102) | completed | Phase 2 | 164 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jun 5, 2019 | clinicaltrials |
| NCT03927495 | KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 100 | Shanghai Chest HospitalOTHER | 1 | May 29, 2019 | clinicaltrials |
| NCT03584308 | Efficacy of VIUSID® Plus GLIZIGEN® in Patients With Papilloma Virus Esophageal | completed | Phase 2 | 110 | Catalysis SLINDUSTRY | 1 | May 22, 2019 | clinicaltrials |
| NCT01248299 | Benefit of Chemotherapy Over Best Supportive Care in Metastatic and Squamous Cell-type Esophageal Cancer.(E-DIS) | terminated | Phase 2 | 105 | Centre Oscar LambretOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT00601705 | Epirubicin, Oxaliplatin and Fluorouracil (EOF) in Cancer of the Esophagus, Gastroesophageal Junction, or Stomach | completed | Phase 2 | 61 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 30, 2019 | clinicaltrials |
| NCT03910634 | IMRT With Carboplatin Versus IMRT With Carboplatin and Fluorouracil for Eldly Esophageal Cancer Patients | unknown | Phase 2 | 264 | Sun Yat-sen UniversityOTHER | 1 | Apr 10, 2019 | clinicaltrials |
| NCT03122548 | Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers | terminated | Phase 2 | 5 | Aduro Biotech, Inc.INDUSTRY | 1 | Apr 4, 2019 | clinicaltrials |
| NCT00917462 | Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT00217581 | Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer | completed | Phase 2 | 39 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Mar 26, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Aug 18, 2020source: clinicaltrials